特邀评论：前列腺癌：少做或许更好。对“早期前列腺癌男性的合并症严重程度与非前列腺癌死亡率”的评论 - Suppr | 超能文献

Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".

作者信息

Ablin Richard J, Sartor Oliver, Bennett Charles L

出版信息

Arch Intern Med. 2010 Aug 9;170(15):1397-9. doi: 10.1001/archinternmed.2010.290.

DOI:10.1001/archinternmed.2010.290

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".特邀评论：前列腺癌：少做或许更好。对“早期前列腺癌男性的合并症严重程度与非前列腺癌死亡率”的评论

Arch Intern Med. 2010 Aug 9;170(15):1397-9. doi: 10.1001/archinternmed.2010.290.

2

Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.关于：引入前列腺特异性抗原筛查后的前列腺癌诊断与治疗：1986 - 2005年

J Natl Cancer Inst. 2010 Apr 7;102(7):506-7. doi: 10.1093/jnci/djq045. Epub 2010 Feb 26.

3

Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer.早期前列腺癌男性患者的共病严重程度与非前列腺癌死亡率

Arch Intern Med. 2010 Aug 9;170(15):1396-7. doi: 10.1001/archinternmed.2010.251.

4

Prostate cancer screening.前列腺癌筛查

Prim Care. 1992 Sep;19(3):637-49.

5

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?为什么前列腺癌筛查的高过度诊断概率和长领先时间如此重要？

J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.

6

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.美国前列腺特异性抗原水平：异常的各种定义的影响

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7. doi: 10.1093/jnci/dji205.

7

Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.年龄、体重指数和血清前列腺特异性抗原与未接受雄激素剥夺治疗的前列腺癌男性的骨质流失相关。

Urology. 2004 Aug;64(2):335-40. doi: 10.1016/j.urology.2004.03.036.

8

Application of prostate-specific antigen in prostate cancer.

MLO Med Lab Obs. 2008 Oct;40(10):54, 56-7.

9

Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.经计算的快速增长型良性前列腺增生——一种发生临床前列腺癌的风险因素。

Scand J Urol Nephrol. 2002;36(5):330-8. doi: 10.1080/003655902320783827.

10

[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].[欧洲前列腺癌筛查随机研究（ERSPC）中前列腺特异性抗原的结果及参与因素：塔恩省和埃罗省的法国部门]

Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28.

引用本文的文献

1

Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study.了解为晚期癌症患者提供化疗的情况：定性访谈研究。

BMJ. 2011 Apr 4;342:d1933. doi: 10.1136/bmj.d1933.